|
Welcome To Stock Marketing Inc!! Sign Up Today!! CYTK,CVGI,CRTP,HSGI,AMCC,OXGN
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (NASDAQ: CYTK) Cytokinetics, Inc., (NASDAQ: CVGI) Commercial Vehicle Group, Inc., (NASDAQ: CRTP) China Ritar Power Corp., (NASDAQ: HGSI) Human Genome Sciences, Inc., (NASDAQ: AMCC) Applied Micro Circuits Corp., (NASDAQ: OXGN) OXiGENE, Inc.
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: CYTK - Cytokinetics, Inc.)
LATEST NEWS!!
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA, Mar 19, 2010 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company's skeletal muscle contractility program. CK-2017357 selectively activates the fast skeletal muscle troponin complex and increases its sensitivity to calcium, resulting in increased skeletal muscle force. In March 2010, CK-2017357 was granted an orphan-drug designation by the United States Food and Drug Administration (FDA) for the potential treatment of ALS.
This Phase IIa EOE clinical trial is a double-blind, randomized, placebo-controlled, three-period crossover, pharmacokinetic and pharmacodynamic study of CK-2017357 in male and female patients with ALS. At least 36 and up to 72 patients may be enrolled in this trial. The primary objective of this trial is to evaluate the pharmacodynamic effects of CK-2017357 on measures of skeletal muscle function or fatigability in patients with ALS. Accordingly, in this hypothesis-generating trial, multiple pharmacodynamic assessments will be made without specifying a single primary pharmacodynamic endpoint. These assessments will include various measures of maximum voluntary muscle strength, development of fatigue at maximum and sub-maximum voluntary muscle contraction, and pulmonary function, measured at baseline, and at 3, 6 and 24 hours post-dosing after each of two single doses of CK-2017357 and placebo. The secondary objectives of this clinical trial are to evaluate the relationship between the plasma concentration of CK-2017357 and its pharmacodynamic effects, to evaluate the safety and tolerability of the two single doses of CK-2017357 administered orally to patients with ALS, and to evaluate the effects of CK-2017357 on patient- and investigator-determined global functional assessments.
"This hypothesis-generating clinical trial is designed to evaluate evidence of pharmacodynamic effects of CK-2017357 associated with potentially increased skeletal muscle performance in patients with ALS. Based on non-clinical and clinical results, we believe that we may demonstrate relevant effects with CK-2017357, even after single dose administration," stated Andrew A. Wolff, MD, FACC, Cytokinetics' Senior Vice President of Clinical Research and Development and Chief Medical Officer. "We believe that results from this trial, as well as those from our other planned Phase IIa 'Evidence of Effect' trial in patients with claudication, have the potential to further inform our understandings of potential therapeutic applications that this novel drug candidate may have in diseases of impaired muscle function." Background on Amyotrophic Lateral Sclerosis Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that afflicts 20,000 to 30,000 people in the United States. Approximately 5,600 new cases of ALS are diagnosed each year. The average life expectancy of an ALS patient is approximately three to five years and only 10% of patients survive for more than 10 years. Death is usually due to respiratory failure because of diminished strength in the skeletal muscles responsible for breathing. Few treatment options exist for these patients, resulting in a high unmet need for new therapeutic options to address the symptoms and modify the disease progression of this grievous illness.
Development Status of CK-2017357 Cytokinetics recently announced data from two Phase I clinical trials evaluating CK-2017357. The first trial is a two-part, single-dose, Phase I clinical trial of CK-2017357. Part A of this trial is designed to assess the safety, tolerability and pharmacokinetic profile of increasing single doses of this drug candidate in healthy volunteers and to determine its maximum-tolerated dose and associated plasma concentrations. To date, single doses up to 2000 mg have been administered without intolerable adverse events being observed. Part B of this trial was designed to assess the pharmacodynamic effects of CK-2017357 on skeletal muscle function after single oral doses of 250, 500 and 1000 mg, and to assess the relationship of the effects observed to the associated plasma concentrations of CK-2017357, also in healthy volunteers. In Part B, CK-2017357 produced concentration-dependent, statistically significant increases versus placebo in the force developed by the tibialis anterior, the muscle evaluated in Part B of this trial. CK-2017357 was well-tolerated and no serious adverse events were reported.
The second trial was a multiple-dose, Phase I clinical trial of CK-2017357 designed to investigate the safety, tolerability and pharmacokinetic profile of CK-2017357 after multiple oral doses to steady state in healthy male volunteers. The trial evaluated doses that produced plasma concentrations in the range associated with pharmacodynamic activity in Part B of the single-dose Phase I study. At steady state, both the maximum plasma concentration and the area under the CK-2017357 plasma concentration versus time curve from before dosing until 24 hours after dosing were generally dose-proportional. In general, systemic exposure to CK-2017357 in this trial was high and inter-subject variability was low. In addition, these multiple-dose regimens of CK-2017357 were well-tolerated, and no serious adverse events were reported. The company believes that these results, in combination with the single-dose Phase I clinical trial data, support progression into Phase IIa "Evidence of Effect" (EoE) clinical trials in patients with neuromuscular diseases and other conditions that may limit mobility, such as the recently opened Phase IIa EOE clinical trial for patients with ALS and a planned Phase IIa EOE clinical trial for patients with claudication.
CK-2017357 has been granted orphan-drug designation by the United States Food and Drug Administration for the potential treatment of ALS.
Background on Cytokinetics Skeletal Muscle Contractility Program CK-2017357, a fast skeletal muscle troponin activator, is the lead drug candidate from the company's skeletal muscle contractility program. CK-2017357 selectively activates the fast skeletal troponin complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle force. This mechanism of action has demonstrated encouraging pharmacological activity in preclinical models that may relate to the potential treatment of diseases associated with aging, muscle wasting or neuromuscular dysfunction. Skeletal muscle contractility is driven by the sarcomere, the fundamental unit of skeletal muscle contraction. It is a highly ordered cytoskeletal structure composed of skeletal muscle myosin, the cytoskeletal motor that is directly responsible for converting chemical energy into mechanical force, as well as actin, and a set of regulatory proteins, troponins and tropomyosin, which make the actin-myosin interaction dependent on changes in intracellular calcium levels. Cytokinetics' skeletal muscle contractility program is focused to the discovery and development of small molecule skeletal sarcomere activators and leverages Cytokinetics' expertise developed in its ongoing discovery and development of cardiac sarcomere activators, including the cardiac myosin activator omecamtiv mecarbil, now in clinical development as a potential treatment for heart failure. Skeletal sarcomere activators have demonstrated pharmacological activity in preclinical models that may lead to new therapeutic options for diseases associated with aging, muscle wasting and neuromuscular dysfunction. The clinical effects of muscle wasting, fatigue and loss of mobility can range from decreased quality of life to, in some instances, life-threatening complications. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere may potentially enhance physical performance and quality of life in aging patients.
About Cytokinetics Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the United States Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: CVGI - Commercial Vehicle Group, Inc.)
LATEST NEWS!!
Commercial Vehicle Group Announces Pricing of Common Stock Offering
NEW ALBANY, Ohio, March 19, 2010 -- Commercial Vehicle Group, Inc. (Nasdaq: CVGI) announced today that it priced a public offering of 3,800,000 shares of common stock at a price of $6.25 per share to the public. The Company will grant the underwriter in the offering an option to purchase up to 570,000 additional shares of common stock at the same price per share to cover any over-allotments. The public offering of the shares is expected to close on March 24, 2010.
Assuming no exercise of the underwriter's over-allotment option, the Company expects to receive net proceeds from the offering of approximately $22 million after deducting underwriting discounts and commissions and estimated expenses of the offering. The Company expects to use the net proceeds from the offering for general corporate and working capital purposes, including the funding of strategic initiatives that the Company may undertake from time to time.
The shares are being offered pursuant to an effective registration statement. This press release does not constitute an offer to sell these securities or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Commercial Vehicle Group, Inc.
Commercial Vehicle Group, Inc. is a leading supplier of fully integrated system solutions for the global commercial vehicle market, including the heavy-duty truck market, the construction and agriculture market and the specialty and military transportation markets. The Company's products include suspension seat systems, interior trim systems, such as instrument and door panels, headliners, cabinetry, molded products and floor systems, cab structures and components, mirrors, wiper systems, electronic wiring harness assemblies and controls and switches specifically designed for applications in commercial vehicle cabs. The Company is headquartered in New Albany, OH with operations throughout North America, Europe and Asia. Information about the Company and its products is available on the internet at www.cvgrp.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: CRTP - China Ritar Power Corp.)
LATEST NEWS!!
China Ritar Power Corp. Joins China Overseas Listed Corporations Association
SHENZHEN, China, March 19, 2010 -- China Ritar Power Corp. (Nasdaq: CRTP) a leading Chinese manufacturer of lead acid batteries, today announced that the Company has joined the China Overseas Listed Corporations Association (COLCA). COLCA is a non-profit organization established on March 7, 2010, with the goal of providing Chinese companies a platform to enhance their knowledge on global capital markets.
"We are extremely excited to join COLCA and believe that with the use of its in-depth resources on global capital markets we will be able to maximize our success as an international listed company," China Ritar's Chairman and CEO, Mr. Jiada Hu stated. "The organization was established to increase Chinese companies' access to information on international capital markets and enhance their competitiveness. Through its unique platform, Chinese companies can now readily acquire and exchange information on issues such as raising capital, reducing operating costs, increasing business development opportunities in China and overseas as well as maximizing shareholder value." About China Ritar Corp. China Ritar designs, develops, manufactures, and markets environmentally friendly lead acid batteries with a wide range of capacities and applications, including telecommunications, uninterruptible power supply (UPS) devices, light electrical vehicles (LEV), and renewable energy systems (solar and wind power). China Ritar sells, markets, and services six series and 197 models of Ritar-branded, cadmium-free, valve-regulated lead-acid (VRLA) batteries. Products are sold worldwide with sales in 81 countries including China, India, and numerous markets in Europe and the Americas. Additional information can be found at the Company's website http://www.ritarpower.com .
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: HGSI - Human Genome Sciences, Inc.)
LATEST NEWS!!
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at the Barclays Capital Healthcare Conference
ROCKVILLE, Md., Mar 19, 2010 -- Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Barclays Capital 2010 Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com A member of Human Genome Sciences' senior management team will present a corporate overview on Wednesday, March 24, 2010, at 2:00 PM Eastern time. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at www.hgsi.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: AMCC - Applied Micro Circuits Corp.)
LATEST NEWS!!
AppliedMicro to Integrate Microsoft RemoteFX With Thin Client Application Processors
Investments in RemoteFX Designed for Compatibility of Thin Client Systems With Rich Media Enhancements in Windows Server 2008 R2
SUNNYVALE, Calif., Mar 19, 2010 -- AppliedMicro (Nasdaq: AMCC), a global leader in energy conscious computing and communications solutions and a provider of thin clients, today announced plans to support Microsoft(R) RemoteFX, a feature being developed for Windows Server(R) 2008 R2 Service Pack 1, in future versions of the AppliedMicro application processors.
AppliedMicro advanced application processors for multimedia thin clients with desktop, applications and storage virtualized in the cloud, is designed to be fully compliant to Microsoft RemoteFX. The company has been working closely with Microsoft to enhance cloud-based remote services enablement and user experience using hardware algorithm-based implementations. The compliance ensures that application processors on the client side will be fully interoperable with the Windows Server 2008 R2 Service Pack 1 and interoperable with the ecosystem of Microsoft RemoteFX(TM) alliances.
"Hardware-based desktop virtualization has been the missing link in increased deployments of multimedia capable thin clients," said Raghu Kondapalli Senior Director of Technology at AppliedMicro. "Traditionally, the high bandwidth and processing requirements of thin clients have kept costs higher relative to personal computers. With RemoteFX technology adoption, cloud-based service deployment becomes economically viable leading to increased adoption of thin clients in consumer and small and medium business environments." "As organizations plan to deploy a centralized computing architecture with virtualized or session-based desktops, IT professionals want to deliver a premium user experience to connected workers," said Mike Schutz, Director of Product Management at Microsoft Corporation. "The Microsoft RemoteFX feature in Windows Server will allow remote workers to access any type of application or screen content, including rich media and 3D applications, and companies such as AppliedMicro are offering a path to the future by investing in solutions today that will increase the flexibility and performance of a centralized desktop environment." AppliedMicro Overview AppliedMicro is a global leader in energy conscious computing and high speed connectivity solutions for telco, enterprise, data center, consumer and SMB applications. With a 30-year heritage as an innovator in high-speed connectivity and high performance embedded processing, AMCC, now AppliedMicro, employs patented Power Architecture(R) SoCs to provide energy efficient products that can deliver up to a 40 percent reduction in power consumption without sacrificing performance. AppliedMicro's corporate headquarters are located in Sunnyvale, California. Sales and engineering offices are located throughout the world. For further information regarding AppliedMicro, visit the company's Web site at http://www.appliedmicro.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: OXGN - OXiGENE, Inc.)
LATEST NEWS!!
OXiGENE Announces Going Concern Opinion On Its Audited Financial Statements for 2009
SOUTH SAN FRANCISCO, Calif., Mar 19, 2010 -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report from its independent registered public accounting firm on its financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 16, 2010, contains an explanatory paragraph regarding the Company's ability to continue as a going concern.
This announcement is required by Nasdaq Marketplace Rule 5250(b)(2), which requires a public announcement of receipt of an audit opinion containing a going concern explanatory paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2009.
About OXiGENE OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To MobilityTechzone Homepage's Homepage ]
|
COMMUNITIES
Technology Marketing Corp. 1997-2011 Copyright. | Ph: 800-243-6002, 203-852-6800; Fx: 203-853-2845 | Contact us 